Drug Safety

, Volume 30, Issue 3, pp 191–194 | Cite as

Poisons Centres and the Reporting of Adverse Drug Events

The Case for Further Development
  • Glyn N Volans
  • Lakshman Karalliedde
  • Heather M Wiseman



The authors have no conflicts of interest that are directly relevant to the content of this editorial.


  1. 1.
    Edwards IR. What is drug safety? Celebrating 20 years of the Drug Safety journal. Drug Saf 2006; 29: 461–5PubMedCrossRefGoogle Scholar
  2. 2.
    Buckley NA, Smith AJ. Evidence-based medicine in toxicology: where is the evidence? Lancet 1996; 347(9009): 1067–9CrossRefGoogle Scholar
  3. 3.
    National Collaborating Centre for Mental Health. Self-harm: short-term physical and psychological management and secondary prevention of self-harm in primary and secondary care. London: The British Psychological Society, 2004Google Scholar
  4. 4.
    Egberts AC, de Koning FH, Meyboom RH, et al. ADR related questions received by a telephone medicines information service and ADRs received by a spontaneous ADR reporting system: a comparison regarding patients and drugs. Pharmacoepidemiol Drug Saf 1997; 6(4): 269–76PubMedCrossRefGoogle Scholar
  5. 5.
    Ponampalam R, Anantharaman V. The need for drug and poison information: the Singapore physicians’ perspective. Singapore Med J 2003; 44(5): 231–42PubMedGoogle Scholar
  6. 6.
    Mey C, Hentschel H, Hippius M, et al. Documentation and evaluation of adverse drug reactions: contribution from a poison information centre. Int J Clin Pharmacol Ther 2002; 40(3): 102–7PubMedGoogle Scholar
  7. 7.
    Fehr JM, Vicas IM-O. Unintentional adult medication exposures: an unrecognized phenomenon. Clin Toxicol 2005; 43(6): 717Google Scholar
  8. 8.
    Butera R, Georgatos J, Arrigoni S, et al. Adverse reactions to intravenous acetylcysteine, effects of reducing the infusion rate of the loading dose. Clin Toxicol 2005; 43(5): 437Google Scholar
  9. 9.
    Mégarbane B, Andriantafika G, Berleur MP, et al. Toxic alcohol exposures and poisoning treated with fomepizole during a 2 year post marketing surveillance in France [abstract]. Clin Toxicol 2005; 43(5): 512–3Google Scholar
  10. 10.
    World Health Organization. Guidelines for poison control [online]. Available from URL: html [Accessed 2007 Jan 3]Google Scholar
  11. 11.
    Descotes J, Testud F. Toxicovigilance: a new approach for the hazard identification and risk assessment of toxicants in human beings. Toxicol Appl Pharmacol 2005; 207: S599–603CrossRefGoogle Scholar
  12. 12.
    World Health Organization. The importance of pharmacovigilance, safety monitoring of medicinal products. Geneva: WHO, 2002Google Scholar
  13. 13.
    Persson HE, Sjoberg GK, Haines JA, et al. Poisoning severity score, grading of acute poisoning. Clin Toxicol 1998; 36(3): 205–313CrossRefGoogle Scholar
  14. 14.
    Chyka PA, McCommon SW. Reporting of adverse drug reactions by poison control centres in the US. Drug Saf 2000; 23(1): 87–93PubMedCrossRefGoogle Scholar
  15. 15.
    Fraunhofer Institute Systems and Innovation Research in collaboration with the Coordination Centre for Clinical Studies at the University Hospital of Tuebingen. An assessment of the community system of pharmacovigilance [online]. Available from URL: [Accessed 2007 Jan 18]Google Scholar
  16. 16.
    Onyon L. Poisons centres and adverse drug reaction reporting: opportunities for greater collaboration. WHO Pharmaceuticals Newsletter 2002; 4: 13–4Google Scholar
  17. 17.
    Abstracts from the North American Congress of Clinical Toxicology Annual Meeting 2005. Clin Toxicol 2005; 43 (6): 631–777Google Scholar
  18. 18.
    Abstracts from the North American Congress of Clinical Toxicology Annual Meeting 2006. Clin Toxicol 2006; 44 (5): 625–783Google Scholar
  19. 19.
    European Association of Poisons Centres and Clinical Toxicologists XXV International Congress, 2005. Clin Toxicol 2005; 43 (5): 387–538Google Scholar
  20. 20.
    Forrester MB. Celecoxib exposures reported to Texas poison control centers from 1999 to 2004. Hum Exp Toxicol 2006; 25(5): 261–6PubMedCrossRefGoogle Scholar
  21. 21.
    Halcomb SE, Nelson LS, Shah C, et al. Telithromycin induced cholinergic crisis in myasthenia gravis. Clin Toxicol 2005; 43(6): 632Google Scholar
  22. 22.
    Wong ICK, Besag FMC, Santosh PJ, et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27(13): 991–1000PubMedCrossRefGoogle Scholar
  23. 23.
    Liang IE, Bird SB, Brush DE, et al. Acute myocardial infarction after infusion of the experimental drug TLK199. Clin Toxicol 2006; 44: 658Google Scholar
  24. 24.
    Woolf AD. Safety evaluation and adverse events monitoring by poison control centers: a framework for herbs and dietary supplements. Clin Toxicol 2006; 44(5): 625–783CrossRefGoogle Scholar
  25. 25.
    Schwamer RA, Hoffman RS, Howland MA, et al. What role does (should?) the PCC play regarding the medication safety of drugs administered off-label. Clin Toxicol 2006; 44: 710Google Scholar
  26. 26.
    BNF for Children. General guidance: supply of medicines. 2nd ed. London: BMJ Publishing Group, Ltd, Royal pharmaceutical Society of Great Britain, RCPH Publications Ltd, 2006Google Scholar
  27. 27.
    Robinson RF, Baker SD, Casavant MJ, et al. Therapeutic error: carboprost tromethamine given to a newborn intramuscularly. Clin Toxicol 2005; 43(6): 636Google Scholar
  28. 28.
    Burda A, Razo M, Wahl M. Therapeutic errors with ranitidine in paediatric patients. Clin Toxicol 2005; 43(6): 639Google Scholar
  29. 29.
    Powers M, Stremski E, Dellinger J, et al. Medication errors in children under 12 months of age. Clin Toxicol 2005; 43(6): 650–1Google Scholar
  30. 30.
    Lewis TV, Schaeffer SE, Hagemann TM, et al. Misleading product packaging contributing to salicylate toxicity in an infant. Clin Toxicol 2005; 43(6): 651Google Scholar
  31. 31.
    Tzimenatos L, Bond GR. Cases of severe injury or death in children resulting from unintentional therapeutic error in a health care facility. Clin Toxicol 2005; 43(6): 651–2Google Scholar
  32. 32.
    Fareed FN, Chan GM, Hoffman FS. Fatal cocaine metoprolol interaction. Clin Toxicol 2005; 43(6): 641Google Scholar
  33. 33.
    Hugman B. The Erice Declaration: the critical role of communication in drug safety. Drug Saf 2006; 29(1): 91–3PubMedCrossRefGoogle Scholar
  34. 34.
    Edwards IR. The WHO World Alliance for Patient Safety. Drug Saf 2005; 28(5): 379–86PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Glyn N Volans
    • 1
  • Lakshman Karalliedde
    • 2
    • 3
  • Heather M Wiseman
    • 4
  1. 1.Department of Clinical Pharmacology, Block 5St Thomas Hospital, Guy’s and St. Thomas’ NHS Foundation TrustLondonUK
  2. 2.Chemical Hazards and Poisons DivisionHealth Protection AgencyLondonUK
  3. 3.King’s College School of MedicineLondonUK
  4. 4.Guy’s and St Thomas’ NHS Foundation TrustLondonUK

Personalised recommendations